Taxanes in adjuvant chemotherapy for early breast cancer.

Adjuvant polychemotherapy improves diseasefree survival and overall survival in women with early breast cancer. A meta-analysis by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) reported that over 15 years there had been a reduction in recurrence and death in women younger than 50 years who had received adjuvant polychemotherapy [1]. A smaller but still highly significant reduction in the risk of recurrence and death was observed for women aged 50–69 years who received the same treatment. The effect of adjuvant chemotherapy on recurrence was noted mainly during the first 5 years after randomization. The magnitude of effect within this 5-year period was 2.5-times greater for women aged under 50 years compared with women aged 50–59 years. The EBCTCG meta-analysis also compared regimens that contain anthracyclines with no chemotherapy or with the oral combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) [1]. The most widely investigated regimens that contain anthracyclines were a combination of cyclophosphamide and 5-fluorouracil with either doxorubicin or epirubicin. The EBCTCG study found that allocation to approximately 6 months of anthracycline-based polychemotherapy reduced the yearly death rate from breast cancer by approximately 38% for women younger than 50 years of age at diagnosis and by approximately 20% for women aged 50–69 years at diagnosis

Deficiency of the purinergic receptor 2X7 attenuates nonalcoholic steatohepatitis induced by high-fat diet. possible role of the NLRP3 Inflammasome

Molecular mechanisms driving transition from simple steatosis to nonalcoholic steatohepatitis (NASH), a critical step in the progression of nonalcoholic fatty liver disease (NAFLD) to cirrhosis, are poorly defined. This study aimed at investigating the role of the purinergic receptor 2X7 (PR2X7), through the NLRP3 inflammasome, in the development of NASH. To this end, mice knockout for the Pr2x7 gene (Pr2x7 −/−) and coeval wild-type (WT) mice were fed a high-fat diet (HFD) or normal-fat diet for 16 weeks. NAFLD grade and stage were lower in Pr2x7 −/− than WT mice, and only 1/7 Pr2x7 −/− animals showed evidence of NASH, as compared with 4/7 WT mice. Molecular markers of inflammation, oxidative stress, and fibrosis were markedly increased in WT-HFD mice, whereas no or significantly reduced increments were detected in Pr2x7 −/− animals, which showed also decreased modulation of genes of lipid metabolism. Deletion of Pr2x7 gene was associated with blunted or abolished activation of NLRP3 inflammasome and expression of its components, which were induced in liver sinusoidal endothelial cells challenged with appropriate stimuli. These data show that Pr2x7 gene deletion protects mice from HFD-induced NASH, possibly through blunted activation of NLRP3 inflammasome, suggesting that PR2X7 and NLRP3 may represent novel therapeutic targets

A Data-Driven Approach to Cyber Risk Assessment

Cyber risk assessment requires defined and objective methodologies; otherwise, its results cannot be considered reliable. The lack of quantitative data can be dangerous: if the assessment is entirely qualitative, subjectivity will loom large in the process. Too much subjectivity in the risk assessment process can weaken the credibility of the assessment results and compromise risk management programs. On the other hand, obtaining a sufficiently large amount of quantitative data allowing reliable extrapolations and previsions is often hard or even unfeasible. In this paper, we propose and study a quantitative methodology to assess a potential annualized economic loss risk of a company. In particular, our approach only relies on aggregated empirical data, which can be obtained from several sources. We also describe how the method can be applied to real companies, in order to customize the initial data and obtain reliable and specific risk assessments

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells

Epidermal growth factor receptor (EGFR), member of the human epidermal growth factor receptor (HER) family, plays a critical role in regulating multiple cellular processes including proliferation, differentiation, cell migration and cell survival. Deregulation of the EGFR signaling has been found to be associated with the development of a variety of human malignancies including lung, breast, and ovarian cancers, making inhibition of EGFR the most promising molecular targeted therapy developed in the past decade against cancer. Human non small cell lung cancers (NSCLC) with activating mutations in the EGFR gene frequently experience significant tumor regression when treated with EGFR tyrosine kinase inhibitors (TKIs), although acquired resistance invariably develops. Resistance to TKI treatments has been associated to secondary mutations in the EGFR gene or to activation of additional bypass signaling pathways including the ones mediated by receptor tyrosine kinases, Fas receptor and NF-kB. In more than 30-40% of cases, however, the mechanisms underpinning drug-resistance are still unknown. The establishment of cellular and mouse models can facilitate the unveiling of mechanisms leading to drug-resistance and the development or validation of novel therapeutic strategies aimed at overcoming resistance and enhancing outcomes in NSCLC patients. Here we describe the establishment and characterization of EGFR TKI-resistant NSCLC cell lines and a pilot study on the effects of a combined MET and EGFR inhibitors treatment. The characterization of the erlotinib-resistant cell lines confirmed the association of EGFR TKI resistance with loss of EGFR gene amplification and/or AXL overexpression and/or MET gene amplification and MET receptor activation. These cellular models can be instrumental to further investigate the signaling pathways associated to EGFR TKI-resistance. Finally the drugs combination pilot study shows that MET gene amplification and MET receptor activation are not sufficient to predict a positive response of NSCLC cells to a cocktail of MET and EGFR inhibitors and highlights the importance of identifying more reliable biomarkers to predict the efficacy of treatments in NSCLC patients resistant to EGFR TKI

Colony shape as a genetic trait in the pattern-forming Bacillus mycoides

BACKGROUND: Bacillus mycoides Flügge, a Gram-positive, non-motile soil bacterium assigned to Bacillus cereus group, grows on agar as chains of cells linked end to end, forming radial filaments curving clock- or counter-clockwise (SIN or DX morphotypes). The molecular mechanism causing asymmetric curving is not known: our working hypothesis considers regulation of filamentous growth as the prerequisite for these morphotypes. RESULTS: SIN and DX strains isolated from the environment were classified as B. mycoides by biochemical and molecular biology tests. Growth on agar of different hardness and nutrient concentration did not abolish colony patterns, nor was conversion between SIN and DX morphotypes ever noticed. A number of morphotype mutants, all originating from one SIN strain, were obtained. Some lost turn direction becoming fluffy, others became round and compact. All mutants lost wild type tight aggregation in liquid culture. Growth on agar was followed by microscopy, exploring the process of colony formation and details of cell divisions. A region of the dcw (division cell wall) cluster, including ftsQ, ftsA, ftsZ and murC, was sequenced in DX and SIN strains as a basis for studying cell division. This confirmed the relatedness of DX and SIN strains to the B. cereus group. CONCLUSIONS: DX and SIN asymmetric morphotypes stem from a close but not identical genomic context. Asymmetry is established early during growth on agar. Wild type bacilli construct mostly uninterrupted filaments with cells dividing at the free ends: they "walk" longer distances compared to mutants, where enhanced frequency of cell separation produces new growing edges resulting in round compact colonies